<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04454567</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-205</org_study_id>
    <secondary_id>UTN 1111-1251-7136</secondary_id>
    <nct_id>NCT04454567</nct_id>
  </id_info>
  <brief_title>A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors</brief_title>
  <official_title>A Phase 2a, Multi-Center, Single-Blind, Placebo-Controlled Study Evaluating Treatment Intensification With ABI-H0731 in Subjects With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the safety and antiviral activity of ABI-H0731 when added to a&#xD;
      nucleos(t)ide reverse transcriptase inhibitor (NrtI) in participants who are partially&#xD;
      virologically suppressed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to a change in the Sponsor's overall development strategy from treatment of&#xD;
    chronic disease to finite, curative treatments, and is based partially on the advice and&#xD;
    feedback from experts and regulators.&#xD;
  </why_stopped>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Actual">April 8, 2021</completion_date>
  <primary_completion_date type="Actual">April 8, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with an Adverse Event</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with Premature Discontinuation of Treatment</measure>
    <time_frame>Up to Week 96</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with a Laboratory Abnormality</measure>
    <time_frame>Up to 120 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants with HBV DNA &lt;Lower Limit of Quantification (LLOQ)</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 HBV DNA</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV DNA &lt;LLOQ</measure>
    <time_frame>Pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV DNA &lt;Limit of Detection (LOD)</measure>
    <time_frame>Pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 HBV Pregenomic RNA (pgRNA)</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with HBV pgRNA &lt;LLOQ</measure>
    <time_frame>Pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B 'e' Antigen (HBeAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B Core-related Antigen (HBcrAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change from Baseline in log10 Serum Hepatitis B Surface Antigen (HBsAg)</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Normalized Alanine Aminotransferase (ALT)</measure>
    <time_frame>Baseline and at pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of ABI-H0731</measure>
    <time_frame>Before dosing and at pre-specified time points after dosing up to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentrations of Entecavir</measure>
    <time_frame>Before dosing and at pre-specified time points after dosing up to Week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HBV Variants Among Participants with Evidence of Non-response to Treatment</measure>
    <time_frame>Pre-specified time points up to Week 120</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>ABI-H0731 + SOC NrtI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with chronic hepatitis B virus (HBV) infection with partial virologic suppression on NrtI alone will receive ABI-H0731 300 mg once daily plus standard of care (SOC) NrtI for 96 weeks, followed by SOC NrtI alone for an additional 24 weeks (120 weeks total).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + SOC NrtI</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with chronic HBV infection with partial virologic suppression on NrtI alone will receive placebo to ABI-H0731 once daily plus SOC NrtI for 48 weeks, followed by ABI-H0731 300 mg once daily plus SOC NrtI for Weeks 48 to 96, followed by SOC NrtI alone for Weeks 96 to 120.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <description>Participants will receive ABI-H0731 tablets orally once daily</description>
    <arm_group_label>ABI-H0731 + SOC NrtI</arm_group_label>
    <arm_group_label>Placebo + SOC NrtI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive placebo to ABI-H0731 tablets orally once daily</description>
    <arm_group_label>Placebo + SOC NrtI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NrtI</intervention_name>
    <description>Entecavir (ETV), tenofovir alafenamide (TAF), or tenofovir disoproxil fumarate (TDF) SOC according to the respective package insert</description>
    <arm_group_label>ABI-H0731 + SOC NrtI</arm_group_label>
    <arm_group_label>Placebo + SOC NrtI</arm_group_label>
    <other_name>Nucleos(t)ide reverse transcriptase inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) 18 to 36 kg/m^2 and a minimum body weight of 45 kg (inclusive)&#xD;
&#xD;
          -  In good general health except for chronic hepatitis B (CHB)&#xD;
&#xD;
          -  HBeAg positive or HBeAg negative chronic hepatitis B&#xD;
&#xD;
          -  HBV DNA &gt;LLOQ using a commercially available assay with LLOQ=20 IU/mL&#xD;
&#xD;
          -  On a stable NrtI regimen (ETV, TDF or TAF) for more than 12 months&#xD;
&#xD;
          -  Lack of cirrhosis or advanced liver disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or prior treatment for CHB with lamivudine, telbivudine, adefovir, HBV core&#xD;
             inhibitor, or previous treatment with an investigational agent for HBV infection&#xD;
&#xD;
          -  Presence of substitutions in the HBV polymerase coding region which may confer reduced&#xD;
             susceptibility to NrtIs&#xD;
&#xD;
          -  Co-infection with human immunodeficiency virus, hepatitis A virus, hepatitis C virus,&#xD;
             hepatitis E virus, or hepatitis D virus&#xD;
&#xD;
          -  Females who are lactating or wish to become pregnant during the course of the trial&#xD;
&#xD;
          -  History or evidence of advanced liver disease or hepatic decompensation&#xD;
&#xD;
          -  Clinically significant cardiac disease including poorly-controlled or unstable&#xD;
             hypertension; pulmonary disease; chronic or recurrent renal or urinary tract disease;&#xD;
             liver disease other than CHB; endocrine disorder; autoimmune disorder; poorly&#xD;
             controlled diabetes mellitus; neuromuscular, musculoskeletal, or mucocutaneous&#xD;
             conditions requiring frequent treatment, seizure disorders requiring treatment;&#xD;
             ongoing infection or other medical conditions requiring frequent medical management or&#xD;
             pharmacologic or surgical treatment that, in the opinion of the Investigator or the&#xD;
             Sponsor, makes the subject unsuitable for trial participation&#xD;
&#xD;
          -  History of hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Exclusionary laboratory parameters at Screening:&#xD;
&#xD;
               -  Platelet count &lt;100,000/mm^3&#xD;
&#xD;
               -  Albumin &lt;lower limit of normal&#xD;
&#xD;
               -  Total bilirubin &gt;1.2 × upper limit of normal (ULN)&#xD;
&#xD;
               -  Direct bilirubin &gt;1.2 × ULN&#xD;
&#xD;
               -  ALT &gt;10 × ULN&#xD;
&#xD;
               -  Serum alpha fetoprotein (AFP) ≥100 ng/mL. If AFP at Screening is &gt;ULN but &lt;100&#xD;
                  ng/mL, the participant is eligible if a hepatic imaging trial prior to initiation&#xD;
                  of study drug reveals no lesions indicative of possible HCC.&#xD;
&#xD;
               -  International Normalized Ratio &gt;1.5 × ULN&#xD;
&#xD;
               -  Glomerular filtration rate &lt;50 mL/min/1.73 m^2 by Chronic Kidney Disease&#xD;
                  Epidemiology Collaboration equation&#xD;
&#xD;
               -  Any other laboratory abnormality deemed clinically significant by the Sponsor or&#xD;
                  the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Knox</last_name>
    <role>Study Director</role>
    <affiliation>Assembly Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asia Pacific Liver Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Liver Research Institute</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research and Education</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schiff Center for Liver Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Human Virology</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Care</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of X.M., MD</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>June 18, 2020</study_first_submitted>
  <study_first_submitted_qc>June 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

